Everything you need to know about why CRISPR is such a hot technology
By Dominic Basulto,
The Washington Post
| 11. 04. 2015
[cites CGS]
Untitled Document
In just the past nine months, venture capitalists have plunked down
more than $200 million in start-up companies developing an innovative gene-editing technology known as CRISPR (Clustered Regularly Interspaced Palindromic Repeats). In 2014,
MIT Technology Review touted this gene-editing technology as
“the biggest biotech discovery of the century.”
At the very least, CRISPR (more formally known as CRISP-Cas9) is the most important innovation in the synthetic biology space in nearly 30 years. Measured against any benchmark — such as the number of patents and scientific publications or the amount of government funding and private sector funding – interest in CRISPR has skyrocketed since 2013.
What CRISPR enables, say its proponents, is a quick, easy and effective way to edit the genes of any species – including humans. Other methods take months or years, while CRISPR speeds that time up to mere weeks. The ability to cut and splice genes so quickly and so precisely has potential applications for the ability to create new biofuels, materials, drugs and foods within much shorter time frames at a relatively low cost.
In...
Related Articles
By Keith Casebonne and Jodi Beckstine [with CGS' Katie Hasson], Disability Deep Dive | 07.24.2025
In this episode of Disability Deep Dive, hosts Keith and Jodi explore the complex interplay between disability science, technology, and ethics with guest Katie Hasson, Associate Director at the Center for Genetics and Society. The conversation delves into...
By Angus Liu, Fierce Pharma | 07.22.2025
A brief skirmish between Sarepta Therapeutics and the FDA has ended before escalating into a full-on regulatory clash, as the company has bowed to the agency’s demand.
In a surprising reversal, Sarepta on Monday said it will pause all shipments...
By Lucy Tu, The Atlantic | 07.11.2025
Donald Trump—who is, by his own accounting, “the fertilization president” and “the father of IVF”—wants to help Americans reproduce. During his 2024 campaign, he promised that the government or insurance companies would cover the cost of in vitro fertilization. In...
By Jared Whitlock, Endpoints News | 07.15.2025
Patient groups face a harder and unpredictable path going state-by-state to boost screening for rare but treatable conditions after the Trump administration disbanded a federal advisory committee on newborn screening.
In April, the Advisory Committee on Heritable Disorders in Newborns...